Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

41. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September

2019 Health Canada - Drug and Health Product Register

42. Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance

Institute for Health and Care Excellence Guidance M. Taremi, E.T. Vella, S. Cheng, P.M. Ellis, R. Goffin, A. Louie, R. MacRae, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: November 11, 2019 This document describes the CCO-Lung Cancer Disease Site Group endorsement of the recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available (...) : Guideline Endorsement ENDORSEMENT The Lung Cancer Disease Site Group of Cancer Care Ontario (CCO) endorses the following clinical recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer (SCLC) found in the Lung cancer: diagnosis and management guideline, published by the National Institute for Health and Care Excellence (NICE) [1]. They are reprinted with the permission of NICE. 1 RECOMMENDATIONS Limited-stage disease SCLC Offer

2019 Cancer Care Ontario

43. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. (Abstract)

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination (...) with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC.This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum

2019 Lancet

44. Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details | CADTH.ca Find the information you need Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Project Number pCODR 10183 Brand Name Lorbrena Generic Name Lorlatinib Tumour Type Lung Indication Non-Small Cell Lung Cancer (NSCLC) Funding Request For the treatment of adult patients with anaplastic (...) lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib. Review Status Under Review Pre Noc Submission No NOC Date Manufacturer Pfizer Canada ULC Sponsor Pfizer Canada ULC Submission Date June 11, 2019 Submission Deemed Complete June 25, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ June 25, 2019 Check-point meeting

2019 CADTH - Pan Canadian Oncology Drug Review

45. Tecentriq for Small Cell Lung Cancer – Details

Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell Lung Cancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC

2019 CADTH - Pan Canadian Oncology Drug Review

46. Metastatic Non-Small-Cell Lung Cancer

for 80%–90% of lung cancers, while small cell lung cancer (SCLC) has been decreasing in frequency in many countries over the past two decades [4]. During the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCC and adenocarcinoma are still increasing [5 (...) epidemiological data have resulted in ‘non-smoking-associated lung cancer’ being considered a distinct disease entity, where specific molecular and genetic tumour characteristics have been identified [14]. Updated version published 18 September 2019 by the ESMO Guidelines Committee © European Society for Medical Oncology 2019. All rights reserved. 2 Use of non-cigarette tobacco products such as cigars and pipes has been increasing. A pooled analysis highlighted the increased risk, particularly for lung

2019 European Society for Medical Oncology

47. Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

48. Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details

Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre

2019 CADTH - Pan Canadian Oncology Drug Review

49. Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Tagrisso for Non-Small Cell Lung Cancer (first line) – Details Project Number pCODR 10137 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer (first line) Funding Request For the first-line (...) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 10, 2018 Manufacturer AstraZeneca Canada Inc. Sponsor AstraZeneca Canada Inc. Submission Date May 16, 2018 Submission Deemed Complete May 24, 2018 Submission Type New Indication Prioritization Requested Requested and Not Granted Stakeholder Input Deadline ‡ May

2019 CADTH - Pan Canadian Oncology Drug Review

50. Pembrolizumab (Keytruda) - metastatic non-squamous non-small cell lung carcinoma (NSCLC)

is summarised as follows: ADVICE: following a resubmission assessed under the end of life process pembrolizumab (Keytruda ® ) is accepted for restricted use within NHSScotland. Indication under review: in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations. SMC restriction: in patients whose tumours express programmed death ligand 1 (PD-L1 (...) accepted pembrolizumab for restricted use in NHSScotland. Other data were also assessed but remain confidential.* Additional information: guidelines and protocols The Scottish Intercollegiate Guidelines Network (SIGN) published guideline number 137, Management of lung cancer in February 2014. The guidance recommends that patients who have advanced disease, are performance status 0 to 1, have predominantly non-squamous NSCLC and are EGFR mutation negative should be offered combination systemic

2019 Scottish Medicines Consortium

51. Vizimpro for Non-Small Cell Lung Cancer – Details

Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details Project Number pCODR 10129 Brand Name Vizimpro Generic Name Dacomitinib Strength 15 mg, 30 mg & 45 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the first-line treatment of patients with locally advanced or metastatic non (...) ‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date February 26, 2019 Manufacturer Pfizer Canada Inc. Sponsor Pfizer Canada Inc. Submission Date September 19, 2018 Submission Deemed Complete October 3, 2018 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ October 3, 2018 Check-point meeting December 4, 2018 pERC Meeting March 21, 2019 Initial

2019 CADTH - Pan Canadian Oncology Drug Review

52. Imfinzi for Non-Small Cell Lung Cancer – Details

Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details Project Number pCODR 10131 Brand Name Imfinzi Generic Name Durvalumab Strength 50 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC

2019 CADTH - Pan Canadian Oncology Drug Review

53. Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Project Number pCODR 10151 Brand Name Xalkori Generic Name Crizotinib Strength 200 mg & 250 mg Tumour Type Lung Indication ROS1-positive advanced Non-Small Cell Lung (...) Cancer Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 28, 2017 Manufacturer Pfizer Canada Inc. Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee Submission Date October 30, 2018 Submission Deemed Complete November 13, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ November 13

2019 CADTH - Pan Canadian Oncology Drug Review

54. ALK Inhibitors for Non–Small Cell Lung Cancer

of the Anaplastic Lymphoma Kinase (ALK) gene drives the development of about 5% of non–small cell lung cancers (NSCLC). Inhibitors of ALK can effectively delay progression of these malignancies and are the treatment of choice in the first-line and subsequent line settings. This drug class is expanding and new products are poised to enter the market. Reviews of the comparative clinical and cost-effectiveness of ALK inhibitors, and of guidelines pertaining to their use, were requested by Canadian decision-makers (...) ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer | CADTH.ca Find the information you need ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer Last updated: February 20, 2019 Project Number: HE0017-000 Product Line: Technology Review Result type: Report Lung cancer is the second-most commonly diagnosed cancer in both men and women, and is the leading cause of cancer deaths in Canada. Rearrangement

2019 CADTH - Technology Review

55. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (Abstract)

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.In this open-label, phase 3 trial, we randomly assigned

2019 NEJM

56. Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment

Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment Daily online image-guided radiotherapy (lung cancer) - Health Technology Wales > Daily online image-guided radiotherapy (lung cancer) Daily online image-guided radiotherapy (lung cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health (...) Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER036 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full

2019 Health Technology Wales

57. Stereotactic ablative body radiotherapy for people with central non-small-cell lung carcinoma

Stereotactic ablative body radiotherapy for people with central non-small-cell lung carcinoma Stereotactic ablative body radiotherapy - Health Technology Wales > Stereotactic ablative body radiotherapy Stereotactic ablative body radiotherapy Topic Status Complete Stereotactic ablative body radiotherapy for people with central non-small-cell lung carcinoma. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer (...) Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER041 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm

2019 Health Technology Wales

58. Volumetric modulated arc radiotherapy for people with lung cancer

Volumetric modulated arc radiotherapy for people with lung cancer Volumetric modulated arc radiotherapy (lung cancer) - Health Technology Wales > Volumetric modulated arc radiotherapy (lung cancer) Volumetric modulated arc radiotherapy (lung cancer) Topic Status Complete Volumetric modulated arc radiotherapy for people with lung cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre (...) . It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER034 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking

2019 Health Technology Wales

59. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)- activating mutations. 1 Dosing Information EGFR mutation status should be established prior to initiation of dacomitinib therapy. The recommended dose of dacomitinib is 45mg taken orally once daily, until disease progression or unacceptable toxicity occurs. Patients should be encouraged to take their dose at approximately the same time each day. Dose modifications may be required based on individual safety and tolerability (...) as adenocarcinoma. Those with recurrent disease were required to have a disease-free interval of =12-months between completing adjuvant or neoadjuvant therapy and recurrence. Patients also had at least one confirmed EGFR mutation (Ex19del or L858R mutation with or without T790M mutation) and at least one measurable target lesion (according to Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) that had not previously been irradiated. They also had Eastern Co-operative Oncology Group (ECOG

2019 Scottish Medicines Consortium

60. Osimertinib (Tagrisso) - non-small cell lung cancer (NSCLC)

. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. 1 Dosing Information Osimertinib 80mg orally once daily (at the same time each day) until disease progression or unacceptable (...) patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations. Clinical expert responses indicate afatinib and erlotinib are the key comparators and afatinib may be the treatment most likely to be displaced in practice, particularly for fitter patients. A partitioned survival model was used with three health states: progression free, progressed disease and death. The model used PFS and OS data to model events over a 20-year time horizon. The source of the clinical data

2019 Scottish Medicines Consortium